-
公开(公告)号：US20110071209A1
公开(公告)日：2011-03-24
申请号：US12847958
申请日：2010-07-30
IPC分类号： A61K31/713 , A61P25/00 , C07H21/04
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节RhoA基因表达的组合物和方法，更具体地说涉及通过化学修饰的寡核苷酸下调RhoA。
-
公开(公告)号：US07772200B2
公开(公告)日：2010-08-10
申请号：US11491367
申请日：2006-07-21
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/346 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节RhoA基因表达的组合物和方法，更具体地说涉及通过化学修饰的寡核苷酸下调RhoA。
-
公开(公告)号：US20120136145A1
公开(公告)日：2012-05-31
申请号：US13165568
申请日：2011-06-21
申请人： David Bumcrot , Pamela Tan , Hans-Peter Vornlocher , Anke Geick
发明人： David Bumcrot , Pamela Tan , Hans-Peter Vornlocher , Anke Geick
IPC分类号： C07H21/02
CPC分类号： C12N15/1138 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2330/30 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
摘要翻译： 本发明涉及用于抑制Eg5基因（Eg5基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 ，并且其与Eg5基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由Eg5表达引起的疾病和使用该药物组合物表达Eg5基因的方法; 以及用于抑制细胞中Eg5基因表达的方法。
-
公开(公告)号：US07718632B2
公开(公告)日：2010-05-18
申请号：US12140112
申请日：2008-06-16
申请人： Gino Van Heeke , Emma Hickman , Henry Luke Danahay , Pamela Tan , Anke Geick , Hans-Peter Vornlocher
发明人： Gino Van Heeke , Emma Hickman , Henry Luke Danahay , Pamela Tan , Anke Geick , Hans-Peter Vornlocher
CPC分类号： C12N15/1138 , A61K31/713 , A61K45/06 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节α-ENaC表达的组合物和方法，更具体地涉及通过化学修饰的寡核苷酸下调α-ENaC表达。
-
公开(公告)号：US20090258934A1
公开(公告)日：2009-10-15
申请号：US12487605
申请日：2009-06-18
申请人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
发明人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
IPC分类号： A61K31/713 , C07H21/02 , C12N5/10 , C12N15/63 , A61P25/00
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
摘要翻译： 本发明涉及用于抑制Nav1.8基因（Nav1.8基因）表达的双链核糖核酸（dsRNA），其包含长度小于25个核苷酸的核苷酸序列的反义链，其基本上 与Nav1.8基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由使用该药物组合物的Nav1.8基因表达引起的疾病的方法; 以及抑制细胞中Nav1.8基因表达的方法。
-
公开(公告)号：US07582745B2
公开(公告)日：2009-09-01
申请号：US11593099
申请日：2006-11-03
申请人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
发明人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
摘要翻译： 本发明涉及用于抑制Nav1.8基因（Nav1.8基因）表达的双链核糖核酸（dsRNA），其包含长度小于25个核苷酸的核苷酸序列的反义链，其基本上 与Nav1.8基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由使用该药物组合物的Nav1.8基因表达引起的疾病的方法; 以及用于抑制细胞中Nav1.8基因表达的方法。
-
公开(公告)号：US07902168B2
公开(公告)日：2011-03-08
申请号：US12487605
申请日：2009-06-18
申请人： Dinah Wen-Yee Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
发明人： Dinah Wen-Yee Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
摘要翻译： 本发明涉及用于抑制Nav1.8基因（Nav1.8基因）表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的反义链，其基本上 与Nav1.8基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由使用该药物组合物的Nav1.8基因表达引起的疾病的方法; 以及抑制细胞中Nav1.8基因表达的方法。
-
公开(公告)号：US20110015250A1
公开(公告)日：2011-01-20
申请号：US12754110
申请日：2010-04-05
申请人： David Bumcrot , Pamela Tan , Hans-Peter Vornlocher , Anke Geick
发明人： David Bumcrot , Pamela Tan , Hans-Peter Vornlocher , Anke Geick
IPC分类号： A61K31/713 , C07H21/02 , A61P35/00 , C12N15/63 , C12N5/071
CPC分类号： C12N15/1138 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2330/30 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
摘要翻译： 本发明涉及用于抑制Eg5基因（Eg5基因）表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸 ，并且其与Eg5基因的至少一部分基本上互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由Eg5表达引起的疾病和使用该药物组合物表达Eg5基因的方法; 以及用于抑制细胞中Eg5基因表达的方法。
-
公开(公告)号：US20070105806A1
公开(公告)日：2007-05-10
申请号：US11593099
申请日：2006-11-03
申请人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
发明人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.
摘要翻译： 本发明涉及用于抑制Nav1.8基因（Nav1.8基因）表达的双链核糖核酸（dsRNA），其包含长度小于25个核苷酸的核苷酸序列的反义链，其基本上 与Nav1.8基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由使用该药物组合物的Nav1.8基因表达引起的疾病的方法; 以及抑制细胞中Nav1.8基因表达的方法。
-
10.发明申请公开(公告)号：US20110124711A1
公开(公告)日：2011-05-26
申请号：US13016896
申请日：2011-01-28
申请人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
发明人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene in a cell.
摘要翻译： 本发明涉及用于抑制Nav1.8基因（Nav1.8基因）表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的反义链，其基本上 与Nav1.8基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由使用该药物组合物的Nav1.8基因表达引起的疾病的方法; 以及抑制细胞中Nav1.8基因表达的方法。
-
-
-
-
-
-
-
-
-
搜索结果
97 条记录 (耗时 0.044 秒)
